SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
XENOPORT
(NQNM:XNPT Last Sale: 5.75 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (XNPT : $5.75)
$174 million Market Cap at September 12, 2013
Employs 100.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
3410 Central Expressway Research Report Earnings Snapshot - Last 11/04/18
Santa Clara, CA 95051 Fact Sheet
Phone: (408) 616-7200 Financial Statements
Peer Comparison
Annual Reports

Ronald W. Barrett, CEO, William G. Harris, CFO
IPO at $10.50 June 1, 2005. Raised $52.5 million, selling 5 million shares, 26% of the outstanding. Lead Manager: Morgan Stanley. Reported results from a Phase 3 clinical trial of XP13512 for the treatment of symptoms of primary restless legs syndrome (RLS) April 25, 2007. February 18, 2010, experimental treatment for restless legs syndrome was not approved by U.S. regulators. July 8, 2010, indicated experimental migraine drug, made with GlaxoSmithKline, did not outperform placebo.
Historical Charts    Technical Analysis
No Historical Data available for XNPT

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common XNPT $5.75 $ 0 $5.67 $6.11 526,615 $4.24 $12.98 30,340
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10129
Common Stock $174,455

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex